These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 25164065)

  • 1. Consideration of the switch from twice-daily to once-daily tacrolimus in pediatric kidney transplant in daily clinical practice: pharmacokinetic parameters, patient satisfaction and medical practices.
    Favennec C; Allain-Launay E; Launay E; Le Grand A; Bertholet-Thomas A; Maisin A; Garnier A; Meriau E; Roussey-Kesler G
    Pediatr Transplant; 2014 Nov; 18(7):777-9. PubMed ID: 25164065
    [No Abstract]   [Full Text] [Related]  

  • 2. A switch from conventional twice-daily tacrolimus to once-daily extended-release tacrolimus in stable kidney transplant recipients.
    Hatakeyama S; Fujita T; Yoneyama T; Yoneyama T; Koie T; Hashimoto Y; Saitoh H; Funyu T; Narumi S; Ohyama C
    Transplant Proc; 2012 Jan; 44(1):121-3. PubMed ID: 22310594
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Therapeutic drug monitoring of once-daily tacrolimus (Advagraf) in a gastrectomized kidney transplant recipient.
    Ma TK; Chow KM; Kwan BC; Leung CB; Szeto CC; Li PK
    Nephrology (Carlton); 2017 Feb; 22(2):184. PubMed ID: 28064453
    [No Abstract]   [Full Text] [Related]  

  • 4. First clinical experience with the new once-daily formulation of tacrolimus.
    First MR
    Ther Drug Monit; 2008 Apr; 30(2):159-66. PubMed ID: 18367975
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Conversion from twice daily tacrolimus capsules to once daily extended-release tacrolimus (LCP-Tacro): phase 2 trial of stable liver transplant recipients.
    Alloway RR; Eckhoff DE; Washburn WK; Teperman LW
    Liver Transpl; 2014 May; 20(5):564-75. PubMed ID: 24493215
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and efficacy of conversion from twice-daily tacrolimus (prograf) to once-daily prolonged-release tacrolimus (graceptor) in stable kidney transplant recipients.
    Nakamura Y; Hama K; Katayama H; Soga A; Toraishi T; Yokoyama T; Kihara Y; Jojima Y; Konno O; Iwamoto H; Takeuchi H; Hirano T; Shimazu M
    Transplant Proc; 2012 Jan; 44(1):124-7. PubMed ID: 22310595
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment satisfaction in renal transplant patients taking tacrolimus once daily.
    van Boekel GA; Kerkhofs CH; Hilbrands LB
    Clin Ther; 2013 Nov; 35(11):1821-9.e1. PubMed ID: 24135441
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of pharmacokinetics and pathology for low-dose tacrolimus once-daily and twice-daily in living kidney transplantation: prospective trial in once-daily versus twice-daily tacrolimus.
    Tsuchiya T; Ishida H; Tanabe T; Shimizu T; Honda K; Omoto K; Tanabe K
    Transplantation; 2013 Jul; 96(2):198-204. PubMed ID: 23792649
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Population pharmacokinetics of tacrolimus in pediatric liver transplantation: early posttransplantation clearance.
    Wallin JE; Bergstrand M; Wilczek HE; Nydert PS; Karlsson MO; Staatz CE
    Ther Drug Monit; 2011 Dec; 33(6):663-72. PubMed ID: 22105583
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics in stable kidney transplant recipients after conversion from twice-daily to once-daily tacrolimus formulations.
    van Hooff J; Van der Walt I; Kallmeyer J; Miller D; Dawood S; Moosa MR; Christiaans M; Karpf C; Undre N
    Ther Drug Monit; 2012 Feb; 34(1):46-52. PubMed ID: 22249344
    [TBL] [Abstract][Full Text] [Related]  

  • 11. No change in insulin sensitivity in renal transplant recipients converted from standard to once-daily prolonged release tacrolimus.
    Midtvedt K; Jenssen T; Hartmann A; Vethe NT; Bergan S; Havnes K; Åsberg A
    Nephrol Dial Transplant; 2011 Nov; 26(11):3767-72. PubMed ID: 21471328
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Conversion of stable kidney transplant recipients from a twice daily Prograf-based regimen to a once daily modified release tacrolimus-based regimen.
    Alloway R; Steinberg S; Khalil K; Gourishankar S; Miller J; Norman D; Hariharan S; Pirsch J; Matas A; Zaltzman J; Wisemandle K; Fitzsimmons W; First MR
    Transplant Proc; 2005 Mar; 37(2):867-70. PubMed ID: 15848559
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetic properties of a once-daily formulation of tacrolimus in patients with renal transplantation.
    Imanishi Y; Matsui K; Ishida K; Ito S; Matsuura K; Deguchi T; Itoh Y
    Arzneimittelforschung; 2011; 61(3):191-6. PubMed ID: 21528645
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Making every drop count for pediatric kidney transplant patients.
    Clark SL; Taylor A; Shaw KN; Copelovitch L
    Hosp Pediatr; 2015 May; 5(5):287-9. PubMed ID: 25934814
    [No Abstract]   [Full Text] [Related]  

  • 15. 0.03% Tacrolimus ointment applied once or twice daily is more efficacious than 1% hydrocortisone acetate in children with moderate to severe atopic dermatitis: results of a randomized double-blind controlled trial.
    Reitamo S; Harper J; Bos JD; Cambazard F; Bruijnzeel-Koomen C; Valk P; Smith C; Moss C; Dobozy A; Palatsi R;
    Br J Dermatol; 2004 Mar; 150(3):554-62. PubMed ID: 15030341
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interaction between everolimus and tacrolimus in renal transplant recipients: a pharmacokinetic controlled trial.
    Pascual J; del Castillo D; Cabello M; Pallardó L; Grinyó JM; Fernández AM; Brunet M
    Transplantation; 2010 Apr; 89(8):994-1000. PubMed ID: 20335831
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of switching from twice-daily to once-daily tacrolimus formulation on quality of life, anxiety, and transplant benefit perception after kidney transplantation.
    Calia R; Lai C; Aceto P; Luciani M; Romagnoli J; Lai S; Gargiulo A; Citterio F
    Transplant Proc; 2011 May; 43(4):1020-3. PubMed ID: 21620041
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetic modeling and development of Bayesian estimators in kidney transplant patients receiving the tacrolimus once-daily formulation.
    Saint-Marcoux F; Debord J; Undre N; Rousseau A; Marquet P
    Ther Drug Monit; 2010 Apr; 32(2):129-35. PubMed ID: 20110850
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Two years postconversion from a prograf-based regimen to a once-daily tacrolimus extended-release formulation in stable kidney transplant recipients.
    Alloway R; Steinberg S; Khalil K; Gourishankar S; Miller J; Norman D; Hariharan S; Pirsch J; Matas A; Zaltzman J; Wisemandle K; Fitzsimmons W; First MR
    Transplantation; 2007 Jun; 83(12):1648-51. PubMed ID: 17589351
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Limited sampling strategy for estimating individual exposure of tacrolimus in pediatric kidney transplant patients.
    Zhao W; Fakhoury M; Baudouin V; Maisin A; Deschênes G; Jacqz-Aigrain E
    Ther Drug Monit; 2011 Dec; 33(6):681-7. PubMed ID: 22011724
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.